¹⁸F-FDG PET/CT based model for predicting malignancy in pulmonary nodules: a meta-analysis

Several studies to date have reported on the development of positron emission tomography (PET)/computed tomography (CT)-based models intended to effectively distinguish between benign and malignant pulmonary nodules (PNs). This meta-analysis was designed with the goal of clarifying the utility of these PET/CT-based conventional parameter models as diagnostic tools in the context of the differential diagnosis of PNs.

Relevant studies published through September 2023 were identified by searching the Web of Science, PubMed, and Wanfang databases, after which Stata v 12.0 was used to conduct pooled analyses of the resultant data.

This meta-analysis included a total of 13 retrospective studies that analyzed 1,731 and 693 malignant and benign PNs, respectively. The respective pooled sensitivity, specificity, PLR, and NLR values for the PET/CT-based studies developed in these models were 88% (95%CI: 0.86–0.91), 78% (95%CI: 0.71–0.85), 4.10 (95%CI: 2.98–5.64), and 0.15 (95%CI: 0.12–0.19). Of these endpoints, the pooled analyses of model sensitivity (I² = 69.25%), specificity (I² = 78.44%), PLR (I² = 71.42%), and NLR (I² = 67.18%) were all subject to significant heterogeneity. The overall area under the curve value (AUC) value for these models was 0.91 (95%CI: 0.88–0.93). When differential diagnosis was instead performed based on PET results only, the corresponding pooled sensitivity, specificity, PLR, and NLR values were 92% (95%CI: 0.85–0.96), 51% (95%CI: 0.37–0.66), 1.89 (95%CI: 1.36–2.62), and 0.16 (95%CI: 0.07–0.35), with all four being subject to significant heterogeneity (I² = 88.08%, 82.63%, 80.19%, and 86.38%). The AUC for these pooled analyses was 0.82 (95%CI: 0.79–0.85).

These results suggest that PET/CT-based models may offer diagnostic performance superior to that of PET results alone when distinguishing between benign and malignant PNs.